PURPOSE 2 will test whether an investigational PrEP (pre-exposure prophylaxis) medicine, lenacapavir, helps reduce the chance of getting HIV through sex. PURPOSE 2 FAQs · Purpose 3 · Study Locations · About the Study

12 сент. 2024 г. · The study evaluated the safety and efficacy of twice-yearly injectable lenacapavir for PrEP compared to once-daily oral emtricitabine/tenofovir ...

13 нояб. 2024 г. · PURPOSE 2 is the second pivotal Phase 3 trial to demonstrate superior efficacy for twice-yearly lenacapavir for the investigational use of HIV ...

26 сент. 2024 г. · The PURPOSE 2 trial reported a 96% reduction in the risk of acquiring HIV among study participants, with 99.9% of individuals using LEN not ...

PURPOSE 2 is evaluating an investigational drug, lenacapavir, and enrolled cisgender men, transgender women, transgender men, and gender non-binary individuals ... Purpose 2 · PURPOSE 2 FAQs · Purpose 1 · Purpose 3

12 сент. 2024 г. · The study evaluated the safety and efficacy of twice-yearly injectable lenacapavir for PrEP compared to once-daily oral emtricitabine/tenofovir ...

PURPOSE 2 is a study to find out if long-acting, injectable (given as a shot) lenacapavir for PrEP is safe and acceptable for adolescents.

12 сент. 2024 г. · The PURPOSE trials are evaluating the safety and efficacy of an investigational, twice-yearly injectable medicine, lenacapavir, to reduce the ...

99.9% of participants remained HIV negative. When compared to the oral PrEP control arm this was reported as showing 96% efficacy.

17 мая 2022 г. · The primary objective of this study is to evaluate the efficacy of lenacapavir (LEN) in preventing the risk of human immunodeficiency virus (HIV) infection.